1 July 2017 in Combustion and Flame
17 October 2018 in Neurosurgery
BACKGROUND: Pediatric epilepsy surgery is a treatment modality appropriate for select patients with debilitating medication-resistant seizures. Previous publications have studied seizure freedom as the main outcome of epilepsy surgery. However, there has been no systematic assessment of the postoperative life quality for these children. OBJECTIVE: To estimate the quality of life (QOL) long-term outcomes after surgery for intractable epilepsy in pediatric patients. METHODS: A systematic search of the PubMed and Cochrane databases was performed. Studies reporting questionnaire-assessed QOL at least 12 months postoperatively were included. QOL means and standard deviations were compared between surgically and medically managed patients, between the preoperative and postoperative state of each patient, and were further stratified into patients achieving seizure freedom, and those who did not. Meta-analysis was performed using fixed effects models for weighted mean differences (WMD), 95% confidence intervals (CI) and sensitivity analyses. Funnel plots and Begg's tests were utilized to detect publication bias. RESULTS: The search yielded 18 retrospective studies, reporting 890 surgical patients. Following epilepsy surgery, children had significant QOL improvement compared to their preoperative state (WMD: 16.71, 95% CI: 12.19-21.22, P < .001) and better QOL than matched medically treated controls (WMD: 12.42, 95% CI: 6.25-18.58, P < .001). Patients achieving total seizure freedom after surgery had significant postoperative QOL improvement (WMD: 16.12, 95% CI: 7.98-24.25, P < .001), but patients not achieving seizure freedom did not achieve statistical significance (P = .79). CONCLUSION: Epilepsy surgery can effectively improve QOL in children with medication-resistant seizures, through seizure freedom, which was associated with the greatest improvement in life quality.
1 May 2020 in Journal of Neurosurgery
OBJECTIVE: The Pipeline embolization device (PED) is a routine choice for the endovascular treatment of select intracranial aneurysms. Its success is based on the high rates of aneurysm occlusion, followed by near-zero recanalization probability once occlusion has occurred. Therefore, identification of patient factors predictive of incomplete occlusion on the last angiographic follow-up is critical to its success.METHODS: A multicenter retrospective cohort analysis was conducted on consecutive patients treated with a PED for unruptured aneurysms in 3 academic institutions in the US. Patients with angiographic follow-up were selected to identify the factors associated with incomplete occlusion.RESULTS: Among all 3 participating institutions a total of 523 PED placement procedures were identified. There were 284 procedures for 316 aneurysms, which had radiographic follow-up and were included in this analysis (median age 58 years; female-to-male ratio 4.2:1). Complete occlusion (100% occlusion) was noted in 76.6% of aneurysms, whereas incomplete occlusion (≤ 99% occlusion) at last follow-up was identified in 23.4%. After accounting for factor collinearity and confounding, multivariable analysis identified older age (> 70 years; OR 4.46, 95% CI 2.30–8.65, p < 0.001); higher maximal diameter (≥ 15 mm; OR 3.29, 95% CI 1.43–7.55, p = 0.005); and fusiform morphology (OR 2.89, 95% CI 1.06–7.85, p = 0.038) to be independently associated with higher rates of incomplete occlusion at last follow-up. Thromboembolic complications were noted in 1.4% and hemorrhagic complications were found in 0.7% of procedures.CONCLUSIONS: Incomplete aneurysm occlusion following placement of a PED was independently associated with age > 70 years, aneurysm diameter ≥ 15 mm, and fusiform morphology. Such predictive factors can be used to guide individualized treatment selection and counseling in patients undergoing cerebrovascular neurosurgery.
27 June 2019 in Neurosurgery
EPEfstathios Papavassiliou
BACKGROUND: Adjacent segment disease (ASD) is an important consideration during decision making for lumbar spinal fusion. OBJECTIVE: To identify risk factors for development of ASD after L4-L5 fusion and differences in incidence between rostral and caudal ASD. METHODS: We retrospectively reviewed all consecutive patients at a single institution who underwent first-time spinal fusion at the L4-L5 level for degenerative spinal disease over a 10-yr period, using posterolateral pedicular screw fixation with or without posterior interbody fusion. ASD was defined as clinical and radiographic evidence of degenerative spinal disease requiring reoperation at the level rostral (L3-L4) or caudal (L5-S1) to the index fusion. RESULTS: Among 131 identified patients, the incidence of ASD requiring reoperation was 25.2% (n = 33). Twenty-four cases (18.3% of the entire cohort) developed rostral ASD (segment L3-L4), 3 cases (2.3%) developed caudal (L5-S1), and 6 cases (4.6%) developed bilateral ASD (both rostral and caudal). Cumulatively, the incidence of caudal ASD was significantly lower than rostral ASD (P < .001). Following multivariate logistic regression for factors associated with ASD reoperation, decompression of segments outside the fusion construct was associated with higher ASD rates (odds ratio [OR] = 2.68, P = .039), as was female gender (OR = 3.55, P = .011), whereas older age was associated with lower ASD incidence (OR = 0.95, P = .011). CONCLUSION: When considering posterior L4-L5 fusion, surgeons should refrain from prophylactic procedures in the L5-S1 level, without clinical indications, because ASD incidence on that segment is reassuringly low.
16 December 2019 in Neurosurgery
Over the past decade, flow diverter technology for endocranial aneurysms has seen rapid evolution, with the development of new devices quickly outpacing the clinical evidence base. However, flow diversion has not yet been directly compared to surgical aneurysm clipping or other endovascular procedures. The oldest and most well-studied device is the Pipeline Embolization Device (PED; Medtronic), recently transitioned to the Pipeline Flex (Medtronic), which still has sparse data regarding outcomes. To date, other flow diverting devices have not been shown to outperform the PED, although information comes primarily from retrospective studies with short follow-up, which are not always comparable. Because of this lack of high-quality outcome data, no reliable recommendations can be made for choosing among flow diversion devices yet. Moreover, the decision to proceed with flow diversion should be individualized to each patient. In this work, we wish to provide a comprehensive overview of the technical specifications of all flow diverter devices currently available, accompanied by a succinct description of the evidence base surrounding each device.